

# Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)

Catalog # BEB-Y12



BIOSYSTEMS  
**Acro**

## Source

Anti-Bevacizumab Antibody (AY12) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

## Clone

AY12

## Species

Mouse

## Isotype

Mouse IgG1/kappa

## Antibody Type

Hybridoma Monoclonal

## Reactivity

Human

## Immunogen

Bevacizumab.

## Specificity

Recognizes Bevacizumab specifically.

## Application

Application	Recommended Usage
ELISA	0.1-100 ng/mL

## Purity

>95% as determined by SDS-PAGE.

## Purification

Protein A purified/ Protein G purified

## Formulation

Lyophilized from 0.22  $\mu$ m filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

## Reconstitution

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

## Storage


For long term storage, the product should be stored at lyophilized state at  $-20^{\circ}\text{C}$  or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- $4-8^{\circ}\text{C}$  for 12 months in lyophilized state;
- $-70^{\circ}\text{C}$  for 12 months under sterile conditions after reconstitution.

## SDS-PAGE



Anti-Bevacizumab Antibody (AY12) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With [Star Ribbon Pre-stained Protein Marker](#)).

Discounts, Gifts,  
and more!




➤ [www.acrobiosystems.com](http://www.acrobiosystems.com)


11/19/2024




**Bioactivity-ELISA**



Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 5 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL (QC tested).




Demonstration of the specificity of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) to the bevacizumab.



Measured by its neutralizing ability in a functional ELISA. Immobilized bevacizumab at 2 µg/mL (100 µL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.

**Bioactivity-SPR**



Anti-Bevacizumab Antibody (AY12) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.

Discounts, Gifts, and more!





## Background

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

## Clinical and Translational Updates

Discounts, Gifts,  
and more!

